The Union Health Ministry has banned 16 fixed-dose drug combinations (FDCs), citing public health concerns. Fixed-dose combinations are medicines that contain two or more active pharmaceutical ingredients in a fixed ratio. According to multiple reports, the decision is intended to protect patients and promote the rational use of scientifically validated and effective medicines.
The outlets describe the move as being driven by concerns that some of these combinations lack adequate therapeutic justification for their use. Several sources also point to potential health risks associated with the banned formulations, including that they may not be appropriately supported by evidence for the conditions they are marketed to treat.
While details vary by report, the common thread is that the ministry’s action follows an assessment of the risk-benefit profile and evidence base of the specific FDCs. The reports frame the ban as part of a broader regulatory effort to remove drug formulations that are not sufficiently justified on scientific grounds or may pose avoidable risks to patients.
